Abstract
Non-transferrin-bound iron (NTBI) is detectable in plasma of β-thalassemia patients with transfusional iron overload. This form of iron may cause oxidative tissue damage and increased iron uptake, into several vital organs. Removal of NTBI species is incomplete and transient using standard intermittent desferrioxamine (DFO) or deferiprone (DFP) monotherapy. Combinations of these or other chelators may improve the protection time from NTBI and increase removal of harmful NTBI species. Curcuminoids from Curcuma longa L. is a naturally occurring phytochemical which shows a wide range of pharmacological properties including anti-oxidative, anti-inflammatory, anti-cancer and ironchelating activities. In this study, the curcuminoids was investigated for NTBI chelation in thalassemic plasma in vitro and for the potential to improve NTBI removal when used with other chelators. Curcumin bound Fe3+ to form a Fe3+-curcumin complex with a predominant absorption at 500 nm. The chemical binding of curcumin was dose- and time-dependent and more specific for Fe3+ than Fe2+. Using a HPLC-based NTBI assay without an aluminium blocking step, curcumin shuttled the iron from Fe3+-NTA complex, giving underestimated NTBI values. At equivalent concentrations DFO, DFP and curcumin decreased plasma NTBI with the order of DFP > DFO > curcumin. None of these chelators removed NTBI completely, but curcumin appeared to increase the rate of NTBI removal when added to DFP. It is proposed that the β-diketo moiety of curcumin participates in the NTBI chelation.
Keywords: Curcumin, cucuminoids, deferiprone, desferrioxamine, iron chelator, labile plasma iron, non-transferrin bound iron, thalassemia
Medicinal Chemistry
Title: Curcumin Contributes to In Vitro Removal of Non-Transferrin Bound Iron by Deferiprone and Desferrioxamine in Thalassemic Plasma
Volume: 3 Issue: 5
Author(s): S. Srichairatanakool, C. Thephinlap, C. Phisalaphong, J. B. Porter and S. Fucharoen
Affiliation:
Keywords: Curcumin, cucuminoids, deferiprone, desferrioxamine, iron chelator, labile plasma iron, non-transferrin bound iron, thalassemia
Abstract: Non-transferrin-bound iron (NTBI) is detectable in plasma of β-thalassemia patients with transfusional iron overload. This form of iron may cause oxidative tissue damage and increased iron uptake, into several vital organs. Removal of NTBI species is incomplete and transient using standard intermittent desferrioxamine (DFO) or deferiprone (DFP) monotherapy. Combinations of these or other chelators may improve the protection time from NTBI and increase removal of harmful NTBI species. Curcuminoids from Curcuma longa L. is a naturally occurring phytochemical which shows a wide range of pharmacological properties including anti-oxidative, anti-inflammatory, anti-cancer and ironchelating activities. In this study, the curcuminoids was investigated for NTBI chelation in thalassemic plasma in vitro and for the potential to improve NTBI removal when used with other chelators. Curcumin bound Fe3+ to form a Fe3+-curcumin complex with a predominant absorption at 500 nm. The chemical binding of curcumin was dose- and time-dependent and more specific for Fe3+ than Fe2+. Using a HPLC-based NTBI assay without an aluminium blocking step, curcumin shuttled the iron from Fe3+-NTA complex, giving underestimated NTBI values. At equivalent concentrations DFO, DFP and curcumin decreased plasma NTBI with the order of DFP > DFO > curcumin. None of these chelators removed NTBI completely, but curcumin appeared to increase the rate of NTBI removal when added to DFP. It is proposed that the β-diketo moiety of curcumin participates in the NTBI chelation.
Export Options
About this article
Cite this article as:
Srichairatanakool S., Thephinlap C., Phisalaphong C., Porter B. J. and Fucharoen S., Curcumin Contributes to In Vitro Removal of Non-Transferrin Bound Iron by Deferiprone and Desferrioxamine in Thalassemic Plasma, Medicinal Chemistry 2007; 3(5) . https://dx.doi.org/10.2174/157340607781745447
DOI https://dx.doi.org/10.2174/157340607781745447 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Coronary Physiology in Contemporary Percutaneous Coronary
Interventions
Current Cardiology Reviews Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery Oxytocin and Eating Disorders: A Narrative Review on Emerging Findings and Perspectives
Current Neuropharmacology The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection
Current Pharmaceutical Design Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology <i>In-Silico</i> Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Personalized Medicine and Molecular Diagnostics for Obesity: Metabolic Systems Reconstruction and Gut Microbiome Biomarkers
Current Pharmacogenomics and Personalized Medicine Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Devices and Methods for Closed Reduction of Diaphyseal Fracture
Recent Patents on Biomedical Engineering (Discontinued) Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5’-Phosphate Decarboxylases
Current Medicinal Chemistry Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery